天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Antineoplastic agents>Antibiotics anticancer drugs>Valrubicin
Valrubicin
  • Valrubicin

Valrubicin NEW

Price $39 $89 $143
Package 1mg 5mg 10mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: Valrubicin CAS No.: 56124-62-0
Purity: 97.41% Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

NameValrubicin
DescriptionValrubicin (AD-32) (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 μM) and has antitumor and anti-inflammatory activity.
Cell ResearchUMSCC5 cells exposed to Valrubicin (2 μM for 3 h), a single dose of radiation (400 cGy), or the combined treatment are cultured for a further 12, 24, or 48 hours. At these times, the cells are collected by trypsinization (0.25%), washed in PBS, and fixed at 5 × 10^6 cells/mL with 95% ethanol. Cells are incubated with ribonuclease (50 μg; 70-90 Kunitz units/mg for 30 min), and the resulting pellet resuspended in and incubated with propidium iodide (0.05 mg/mL for 10 min). The DNA content of the samples is determined by flow cytometry according to standard technique [2].
Animal ResearchHamsters with cheek pouch tumors of 100 mm2 are randomly assigned to one of five treatment groups. Momentarily anesthetized animals each receives once a week × 3 injections (27 g × 0.5-inch needle: 0.1 mL administered slowly to the base of the lesion) of Valrubicin (3, 6, or 9 mg) or drug vehicle (Cremophor: alcohol;1:1 by volume; NaCl diluent 12). A further group of animals receives anesthesia but no direct tumor treatment (control). Individual tumor sizes are measured with calipers at weekly intervals for 4 weeks, at which time the animals are sacrificed [2].
In vitroValrubicin inhibits the binding of [3H]PDBu to PKC. Therefore, Valrubicin competes with the tumor promoter for the PKC binding site and prevents the latter from both interacting with the phospholipid and binding to PKC [1]. Valrubicin shows cytotoxic activity against squamous cell carcinoma (SCC) cell line colony formation, with IC50s and IC90s of 8.24 μM and 14.81 μM for UMSCC5 cells, 15.90 μM, 29.84 μM for UMSCC5/CDDP? cells, and 10.50 μM, 19.00 μM for UMSCC10b cells, respectively [2].
In vivoValrubicin, administered at doses of 3, 6, or 9 mg, effectively reduces tumor growth through intratumoral injections in hamsters by the third week. When 6 mg of Valrubicin is used in conjunction with minimally cytotoxic irradiation (ranging from 150, 250, or 350 cGy), it induces significant tumor shrinkage in the hamster model [2]. Additionally, at a concentration of 0.1 μg/μL, Valrubicin markedly decreases the infiltration of neutrophils in TPA-challenged biopsies at 24 hours and mitigates chronic inflammation in mice. Furthermore, Valrubicin reduces the expression of inflammatory cytokines in the acute experimental setup [3].
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationDMSO : 125 mg/mL (172.74 mM)
H2O : Insoluble
KeywordsValrubicin | Protein kinase C | PKC | Inhibitor | inhibit | Antibiotic | AD32 | AD 32
Inhibitors RelatedNeomycin sulfate | Ampicillin sodium | Doxycycline (hyclate) | Cefaclor monohydrate | Kanamycin sulfate | G-418 disulfate | Sulfamethoxazole sodium | Metronidazole | Doxycycline | Penicillin G sodium salt | EDTA copper(II) disodium salt | Dexamethasone
Related Compound LibrariesBioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library | Anti-Cancer Drug Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

  • CAS:1175526-27-8

    $31.00 / 1mg

  • CAS:1983924-33-9

    $117.00 / 1mg

  • CAS:2271358-64-4

    $31.00 / 1mg

Recommended supplier

Product name Price   Suppliers Update time
$1990.00/1g
VIP1Y
R&D Scientific Inc.
2024-02-02
$15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
2021-07-10
$1.10/1g
VIP4Y
Dideu Industries Group Limited
2021-07-01
$0.00/1Kg
VIP6Y
Shaanxi Dideu Medichem Co. Ltd
2020-04-30
$0.00/1g
Beijing Yibai Biotechnology Co., Ltd
2019-08-27
$3.00/3KG
VIP7Y
Career Henan Chemical Co
2019-08-07
$15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
2021-07-08
$15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
2021-06-26
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY